- Opinion
- [Reporter's view] Consistency in the post evaluation
- by Lee, Tak-Sun Mar 7, 2022 05:49am
- Re-evaluation of drugs is underway. The move is aimed at preventing waste of health insurance benefits due to insufficient drugs to verify efficacy. Accordingly, the MFDS is playing a leading role in re-evaluating clinical trials and the HIRA is playing a leading role in re-evaluating the adequacy of benefits. The problem is that there is no
- Company
- First RSA drug ‘Erbitux’ to receive second reevaluations
- by Eo, Yun-Ho Mar 4, 2022 05:57am
- The term of risk-sharing agreements of major anticancer drugs are again nearing expiry. Starting with Merck’s ‘Erbitux (cetuximab), the first drug to be reimbursed with the RSA scheme in Korea, a series of other drugs are also awaiting reevaluations until 2023. According to industry sources, the colorectal cancer treatment Erbitux’s
- Policy
- Brukinsa was approved using phase 2 data on MCL indications
- by Lee, Hye-Kyung Mar 4, 2022 05:57am
- Brukinsa 80mg (Zanubrutinib), the first new drug in Korea by Chinese pharmaceutical company Beijing, has secured MCL indications only with therapeutic clinical trial data (phase 2). This is because there was an expert opinion that according to Article 7, No. 6 of the Regulations on Item Permission, Report, and Review of Medicines, it could r
- Policy
- Janumet's salt change consigned drug have been approved for
- by Lee, Hye-Kyung Mar 4, 2022 05:57am
- A large number of Janumet's salt change combination, which is commissioned and manufactured by Daewon Pharmaceutical, have been approved for items. The MFDS applied for a diabetes complex by Jin Yang, Young Poong, Withus, and Neo Bio Korea Pharm on the 2nd. 8 items of Sitaglipin HCl+Metformin and Colloidal Silicon Dioxide have been approve
- Company
- ↓↓Sales of smoking cessation txs by 75% in 4 yrs
- by Ji Yong Jun Mar 4, 2022 05:56am
- The market for Varenicline, a non-smoking supplement, has fallen to a quarter in four years. This is because the distribution of the original drug Pfizer Champix, which led the market, was suspended due to an impurity crisis in the second half of last year. According to IQVIA, a pharmaceutical research institute, sales of Varenicline last year
- Company
- Kyowa Kirin·Boryung to copromote sale of 2 neutropenia txs
- by Chon, Seung-Hyun Mar 4, 2022 05:55am
- Boryung Pharmaceutical and Kyowa Kirin Korea will be jointly selling 2 types of neutropenia treatments in Korea. On the 2nd, Kyowa Kirin Korea and Boryung Pharmaceutical announced that the companies signed a co-promotion agreement to jointly sell the neutropenia treatments ‘Grasin (filgrastim)’ and ‘Neulasta (pegfilgrastim)’ in Kore
- Company
- Saxenda and Qsymia tops the growing obesity market
- by Chon, Seung-Hyun Mar 3, 2022 06:01am
- The obesity treatment market has grown to break its own record for 3 consecutive years. The introduction of a new type of obesity treatment such as ‘Saxenda’ and ‘Qsymia’ had also led to market expansion.’ The two drugs have dominated the share of existing products and have occupied about half of the total market. According to market res
- Company
- BRAF I Braftovi can be prescribed at the Big 5
- by Eo, Yun-Ho Mar 3, 2022 06:01am
- Along with the progress of the insurance benefit procedure, "Braftovi," which lowers the BRAF, will be prescribed at general hospitals. According to related industries, Braftovi (Encorafenib), a treatment for colorectal cancer in Ono Pharmaceutical Industry, passed the Pharmaceutical Affairs Committee (DC) of Korea University Anam Hospita
- Company
- Entresto settles in as early-stage heart failure treatment
- by Eo, Yun-Ho Mar 3, 2022 06:01am
- The heart failure treatment ‘Entresto’ will now be covered by insurance benefits in the first line as well. According to industry sources, reimbursement for Novartis Korea’s chronic heart failure treatment ‘Entresto (sacubitril)’ will be expanded to cover patients with acute decompensated heart failure who are in a stable hemodynamic
- Policy
- Ahn Cheol Soo, promised for Vaccine Sovereignty
- by Lee, Jeong-Hwan Mar 3, 2022 06:00am
- Like other party candidates, the presidential candidate of the People's Party Ahn Cheol Soo also put securing vaccine sovereignty and fostering the pharmaceutical bio-industry at the forefront of health care pledges. It also announced specific pledges such as half-price hair loss drugs, free vaccination against rotavirus in newborns, supp
